bay-11-7082 and Neuroblastoma

bay-11-7082 has been researched along with Neuroblastoma* in 2 studies

Other Studies

2 other study(ies) available for bay-11-7082 and Neuroblastoma

ArticleYear
Multiple approaches to repurposing drugs for neuroblastoma.
    Bioorganic & medicinal chemistry, 2022, 11-01, Volume: 73

    Neuroblastoma (NB) is the second leading extracranial solid tumor of early childhood with about two-thirds of cases presenting before the age of 5, and accounts for roughly 15 percent of all pediatric cancer fatalities in the United States. Treatments against NB are lacking, resulting in a low survival rate in high-risk patients. A repurposing approach using already approved or clinical stage compounds can be used for diseases for which the patient population is small, and the commercial market limited. We have used Bayesian machine learning, in vitro cell assays, and combination analysis to identify molecules with potential use for NB. We demonstrated that pyronaridine (SH-SY5Y IC

    Topics: Bayes Theorem; Cell Line, Tumor; Child; Child, Preschool; Crizotinib; Drug Repositioning; Etoposide; Fingolimod Hydrochloride; Humans; Neuroblastoma; Niclosamide

2022
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
    Journal of the National Cancer Institute, 2009, May-06, Volume: 101, Issue:9

    Clusterin expression in various types of human cancers may be higher or lower than in normal tissue, and clusterin may promote or inhibit apoptosis, cell motility, and inflammation. We investigated the role of clusterin in tumor development in mouse models of neuroblastoma.. We assessed expression of microRNAs in the miR-17-92 cluster by real-time reverse transcription-polymerase chain reaction in MYCN-transfected SH-SY5Y and SH-EP cells and inhibited expression by transfection with microRNA antisense oligonucleotides. Tumor development was studied in mice (n = 66) that were heterozygous or homozygous for the MYCN transgene and/or for the clusterin gene; these mice were from a cross between MYCN-transgenic mice, which develop neuroblastoma, and clusterin-knockout mice. Tumor growth and metastasis were studied in immunodeficient mice that were injected with human neuroblastoma cells that had enhanced (by clusterin transfection, four mice per group) or reduced (by clusterin short hairpin RNA [shRNA] transfection, eight mice per group) clusterin expression. All statistical tests were two-sided.. Clusterin expression increased when expression of MYCN-induced miR-17-92 microRNA cluster in SH-SY5Y neuroblastoma cells was inhibited by transfection with antisense oligonucleotides compared with scrambled oligonucleotides. Statistically significantly more neuroblastoma-bearing MYCN-transgenic mice were found in groups with zero or one clusterin allele than in those with two clusterin alleles (eg, 12 tumor-bearing mice in the zero-allele group vs three in the two-allele group, n = 22 mice per group; relative risk for neuroblastoma development = 4.85, 95% confidence interval [CI] = 1.69 to 14.00; P = .005). Five weeks after injection, fewer clusterin-overexpressing LA-N-5 human neuroblastoma cells than control cells were found in mouse liver or bone marrow, but statistically significantly more clusterin shRNA-transfected HTLA230 cells (3.27%, with decreased clusterin expression) than control-transfected cells (1.53%) were found in the bone marrow (difference = 1.74%, 95% CI = 0.24% to 3.24%, P = .026).. We report, to our knowledge, the first genetic evidence that clusterin is a tumor and metastasis suppressor gene.

    Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Clusterin; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Haplotypes; Humans; Immunohistochemistry; Luciferases; Mice; Mice, Transgenic; MicroRNAs; N-Myc Proto-Oncogene Protein; Neoplasm Staging; Neuroblastoma; NF-kappa B; Nitriles; Nuclear Proteins; Oncogene Proteins; Polymerase Chain Reaction; RNA, Small Interfering; Sulfones; Transfection; Transplantation, Heterologous

2009